Abstract: An apparatus useful for preventing the release of residual liquid in a beverage brewing device prior to and after the brewing process, and for preventing the premature release of liquid during the heating process is disclosed. The apparatus includes a flexible member, a closing member and a recess. The apparatus is fabricated such that the pressure of the liquid being delivered to the brewing chamber displaces or depresses the closing member sufficiently into the recess to form a first fluid passage. The pressure of the fluid also creates a channel or cavity on a surface of the flexible member. The first fluid passage and the channel or cavity form a second fluid passages which provide fluid communication between the fluid inlet and the brewing chamber. Preferably, the flexible member, closing member and recess is formed as an integral unit.

Abstract: Peptides derived from the peptide CMS-010, which has the formula VAPEEHPTLLTEAPLNPK, are disclosed with their use as pharmaceutical compositions. A method is also disclosed for making a pharmaceutical composition comprising providing a peptide derived from CMS-010 and mixing said peptide with a pharmaceutical acceptable carrier.

Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.

Abstract: A substantially pure and biologically active peptides consisting of tyrosyl-seryl-leucine (YSL) is disclosed. Nucleic acids that have sequences coding for the biologically active peptide and pharmaceutical formulation produced therefrom are also disclosed.

Abstract: The tripeptide Tyrosyl-seryl-valine is disclosed with its use as a nutritional supplement. A method of making a nutritional supplement comprising obtaining the tripeptide Tyrosyl-seryl-valine and mixing the tripeptide with a biologically or therapeutically acceptable carrier is also disclosed.

Abstract: The present invention pertains to a brewing filter apparatus capable of preparing foam, froth, or crema, particularly for coffee beverages, under low pressure. The apparatus can operate at pressures below 15 bar and as low as 1-3 bar. The apparatus comprises a mesh cover, coarse filter, fine filter, large 0-ring, coffee container, small 0-ring, and foam maker having two opposing holes. The holes have a diameter in the range of 0.3 to 1 mm. The crema is created by the turbulent contacting of two opposing jets of coffee, which enter the foam maker through the two opposing holes. To further increase agitation and the surface area for contact, a stainless steel wire mesh may be situated in the center of the foam maker directly in the path of and in between the opposing jets of coffee to facilitate the formation of more crema.

Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced thereform are also disclosed.

Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.

Abstract: The tripeptide Tyrosyl-seryl-valine is disclosed with its use as a pharmaceutical composition. A method is also disclosed making a pharmaceutical composition comprising providing the tripeptide Tyrosyl-seryl-valine and mixing said tripeptide with a pharmaceutical acceptable carrier.

Abstract: An application manager for enabling multiple applications to share resources in a shared and distributed computing environment. The disclosed system provides for the specification, representation and automatic analysis of resource requirements of applications in a shared and distributed computing environment. The application manager is provided with service specifications for each application, which defines the resource requirements necessary or preferred to run said application (or more precisely, its constituent application components). In addition, the resources may be required to have certain characteristics and constraints may be placed on the required resources. The application manager works in conjunction with a resource supply manager and requests the required resources be supplied for the application. If there are appropriate and sufficient available resources to meet the particular resource requirements, then the resources are allocated, and the application components mapped thereon.

Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.

Abstract: The tripeptide Tyrosyl-seryl-valine is disclosed with its use as a pharmaceutical composition in treating a condition whose effects can be reduced by stimulating T-cell transformation and a cell proliferative disorder. A method is also disclosed making a pharmaceutical composition comprising providing the tripeptide Tyrosyl-seryl-valine and mixing said tripeptide with a pharmaceutical acceptable carrier.

Abstract: Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.

Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced thereform are also disclosed.

Abstract: The peptide Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine (SEQ ID NO.1) is disclosed with its use as a pharmaceutical composition in reducing symptoms of viral disease and stimulating properties of immune system in a subject. A method is also disclosed for making a pharmaceutical composition comprising providing an Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine (SEQ ID NO.1) peptide and mixing said peptide with a pharmaceutical acceptable carrier.

Abstract: Peptides derived from the peptide CMS-010, which has the formula VAPEEHPTLLTEAPLNPK, are disclosed with their use as pharmaceutical compositions. A method is also disclosed for making a pharmaceutical composition comprising providing a peptide derived from CMS-010 and mixing said peptide with a pharmaceutical acceptable carrier.

Abstract: Peptides derived from the peptide CMS-010, which has the formula VAPEEHPTLLTEAPLNPK, are disclosed with their use as pharmaceutical compositions. A method is also disclosed for making a pharmaceutical composition comprising providing a peptide derived from CMS-010 and mixing said peptide with a pharmaceutical acceptable carrier.

Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.

Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.

Abstract: The peptide Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine is disclosed with its use as a pharmaceutical composition. A method is also disclosed for making a pharmaceutical composition comprising providing an Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine peptide and mixing said peptide with a pharmaceutical acceptable carrier.